Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.64 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 6/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648250 | 1.00 | PARP10 (0.64) | PARP10PARP11PRCPPARP1BCHE | |
| SCHEMBL14785203 | 0.89 | PARP10 (0.51) | PARP10PARP11PRCPBCHEKDM4E | |
| SCHEMBL20539302 | 0.86 | NOTUM (0.47) | PARP10PARP11PARP1BCHEACHE | |
| SCHEMBL30916119 | 0.86 | NOTUM (0.47) | PARP10PARP11PARP1BCHEACHE | |
| SCHEMBL15312190 | 0.85 | PARP10 (0.47) | PARP10PARP11PRCPPARP1BCHE | |
| SCHEMBL31121854 | 0.85 | PARP10 (0.47) | PARP10PARP11PRCPPARP1BCHE | |
| SCHEMBL5871204 | 0.84 | PARP10 (0.46) | PARP10PARP11PARP1NOTUMHTR2C | |
| SCHEMBL10921073 | 0.81 | PARP10 (0.48) | PARP10PARP11NOTUMHTR2C | |
| SCHEMBL30422322 | 0.81 | PARP1 (0.50) | PARP10PARP11PARP1BCHEACHE | |
| SCHEMBL30421478 | 0.81 | PARP10 (0.48) | PARP10PARP11NOTUMHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110903288-B | Imidazaphenanthridine compound and preparation method and application thereof | 浙江大学 | 2021-02-23 | — | — | CN | claimed |
| CN-110903288-A | Imidazaphenanthridine compound and preparation method and application thereof | 浙江大学 | 2020-03-24 | — | — | CN | claimed |
| CN-119822910-A | Method for catalyzing heterogeneous reduction of nitrogen-containing heterocyclic compound by using magnesium metal | 延安大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024188107-A1 | INDOLINE COMPOUND CONTAINING THIAZOLE STRUCTURE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 沈阳药科大学 | 2024-09-19 | — | — | WO | disclosed |
| EP-4400558-A1 | PHOTON UPCONVERSION COMPOSITION, FILM, MYOPIA-SUPPRESSING TRANSPARENT PRODUCT, AND METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT | Kyushu University, National University Corporation (JP) | 2024-07-17 | — | — | EP | disclosed |
| CN-116283971-B | Indoline compound containing condensed heterocyclic structure, and preparation method and application thereof | 沈阳药科大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-116283953-B | Indoline compound containing thiazole structure, and preparation method and application thereof | 沈阳药科大学 | 2024-02-02 | — | — | CN | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| WO-1997006144-A1 | 2-CARBOCYCLIC AND 2-HETEROCYCLIC QUINOLINE-4-CARBOXYLIC ACIDS AND SALTS THEREOF USEFUL AS IMMUNOSUPPRESSIVE AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5578609-A | INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE, ANTITUMOR, TREATMENT OF ORGAN REJECTION | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| US-5523408-A | USED FOR TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION, GRAFT VERSUS HOST DISEASE, CHRONIC INFLAMMATORY DISEASES LIKE PSORIASIS, RHEUMATOID ARTHRITIS IN MAMMAL | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0089426-B1 | 2-AMINO-6-BIPHENYLACETIC ACIDS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | PARP10 2329/4885PARP11 2739/4885PRCP 2729/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | PARP10 1705/4885PARP11 2302/4885PRCP 3055/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | PARP10 2448/4885PARP11 1317/4885PRCP 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.